Investigating how Gab2 signaling affects inflammation and blood clotting.
Official title: The Role of Gab2 Signaling in Thromboinflammation
Funded at University of Texas Hlth Ctr at Tyler · NIH-10570278 · Data updated 2026-11-12
This study is looking at a protein called Gab2 to see how it affects inflammation and blood clotting, which could help us understand conditions like blood clots in the veins, and the findings might lead to better treatments for patients dealing with these issues.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Ctr at Tyler NIH-funded |
| Lab location | 1 site (Tyler, United States) |
| Project start | February 10, 2022 |
| Project end | January 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $220,500 |
| NIH project number | 5R21AI163558-02 |
| Project ID | NIH-10570278 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with conditions associated with thromboinflammation, such as venous thromboembolism, rheumatoid arthritis, or other inflammatory diseases.
✕Less likely to help
Patients with non-inflammatory conditions or those not affected by thromboinflammation may not receive any benefit from this research.
What this research studies
This research focuses on understanding the role of Gab2, a protein that helps cells respond to inflammation, in the context of thromboinflammation, which is the interplay between inflammation and blood clotting. By examining how Gab2 interacts with various receptors and signaling pathways, the study aims to uncover mechanisms that lead to conditions like venous thromboembolism (VTE). Patients may benefit from insights gained about how inflammatory responses can lead to blood clotting issues, potentially informing new treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for conditions related to excessive inflammation and blood clotting.
How similar studies have gone: Previous research has shown that targeting inflammatory pathways can lead to significant advancements in treating thromboembolic conditions, suggesting that this approach has potential for success.
Where this research is happening
-
University of Texas Hlth Ctr at Tyler
Tyler, United States Active
Researchers
- Principal investigator: Lella, Vijaya Mohan Rao — University of Texas Hlth Ctr at Tyler
- Study coordinator: Lella, Vijaya Mohan Rao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.